The AZD1222 vaccine, developed by the British-Swedish company AstraZeneca and the University of Oxford, showed an average efficacy of 70 percent. This is reported on the pharmaceutical company website .
During the tests, two variants of vaccine administration were tested. In the first case, more than 2.7 thousand people AZD1222 was injected first in a half dose, and a month later in full, and the effectiveness was 90 percent. The variant with the introduction of two full doses with a difference in a month was tested on 9 thousand people and the result was only 62 percent. The combined analysis of both dosing regimens showed an average efficacy of 70 percent.
Also, in the course of research, it turned out that protection against COVID-19 appears 14 days after receiving two doses of the vaccine. There were no severe cases of the disease in participants in the AZD1222 trial.
In September, AstraZeneca suspended trials of its COVID-19 vaccine after one of the study participants contracted transverse myelitis (inflammation of the spinal cord). Later, in October, it became known about the death of one of the volunteers of the national vaccine trials against AstraZeneca. It turned out that the test taker received a placebo and the company continued testing.